# Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

> **NCT03468790** · PHASE3 · COMPLETED · sponsor: **Shanghai Biomabs Pharmaceutical Co., Ltd.** · enrollment: 393 (actual)

## Conditions studied

- Asthma, Allergic

## Interventions

- **DRUG:** CMAB007
- **DRUG:** Symbicort
- **DRUG:** Seretide
- **DRUG:** Ventolin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03468790
- **Lead sponsor:** Shanghai Biomabs Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-09
- **Primary completion:** 2021-01-12
- **Final completion:** 2021-03-09
- **Target enrollment:** 393 (ACTUAL)
- **Last updated:** 2021-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03468790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03468790, "Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03468790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*